Medifocus Asia ( Medifocus) has entered into an advisory agreement with Euro Japan Marketing and Maxim Group to help identify distribution and joint venture (JV) partners for Medifocus' Prolieve thermodilatation system for the treatment of benign prostatic hyperplasia (BPH) in Japan and South Korea.
Under the terms of the agreement, Euro Japan and Maxim Group will serve as co-advisors to Medifocus Asia, as it works to expand its presence throughout Japan and South Korea. They will help identify distribution and joint partners which can further the company's position within the BPH treatment market.
Medifocus stated that it has already made significant progress in its effort to build its presence in the Asia-Pacific market, through a JV partnership with Ideal Concept Group (ICG). ICG and Medifocus own 60% and 40% of Medifocus Asia.